Eléments de l'association

	Robert A. Hauser	27
	disease modification	3
	Robert A. Hauser *Sauf* disease modification"	25
	disease modification *Sauf* Robert A. Hauser"	1
	Robert A. Hauser Et disease modification	2
	Robert A. Hauser Ou disease modification	28
	*Corpus*	4598

List of bibliographic references

Number of relevant bibliographic references: 2.

Ident.	Authors (with country if any)	Title
000A43	Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël]	Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
000E78	C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]	A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024